Literature DB >> 20303002

Restless legs syndrome with carbamazepine-induced osteomalacia: causal or casual association.

Sanjay Prakash1, Roopal J Bhanvadia, Nilima D Shah.   

Abstract

Restless legs syndrome (RLS) is a sensorimotor sleep-related disorder which can be idiopathic or secondary. Secondary RLS is associated with a variety of conditions. Here we report a 16-year-old girl with RLS secondary to vitamin D deficiency (VDD) caused by chronic administration of carbamazepine. We also speculate on the possible mechanisms for the development of RLS in patient with VDD. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20303002     DOI: 10.1016/j.genhosppsych.2009.03.003

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  4 in total

1.  Efficacy of vitamin D replacement therapy in restless legs syndrome: a randomized control trial.

Authors:  Siraj Omar Wali; Bahaa Abaalkhail; Faris Alhejaili; S R Pandi-Perumal
Journal:  Sleep Breath       Date:  2018-11-14       Impact factor: 2.816

2.  The effect of vitamin D supplements on the severity of restless legs syndrome.

Authors:  Siraj Wali; Afnan Shukr; Ayah Boudal; Ahmad Alsaiari; Ayman Krayem
Journal:  Sleep Breath       Date:  2014-08-23       Impact factor: 2.816

3.  The Association Between Vitamin D Level and Restless Legs Syndrome: A Population-Based Case-Control Study.

Authors:  Siraj Wali; Samah Alsafadi; Bahaa Abaalkhail; Iman Ramadan; Badr Abulhamail; Moaiyyad Kousa; Reem Alshamrani; Hanan Faruqui; Abdulaziz Faruqui; Mohamed Alama; Mohamed Hamed
Journal:  J Clin Sleep Med       Date:  2018-04-15       Impact factor: 4.062

4.  In search of risk factors for chronic pain in adolescents: a case-control study of childhood and parental associations.

Authors:  Alies Coenders; Cindy Chapman; Patricia Hannaford; Tiina Jaaniste; Wen Qiu; David Anderson; Maline Glogauer; Evelyn Goodison-Farnsworth; Marianne McCormick; David Champion
Journal:  J Pain Res       Date:  2014-03-27       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.